摘要
肺癌是中国乃至全球发病率最高的恶性肿瘤,占癌症死亡因素的首位,其中约85%为非小细胞肺癌(non-small cell lung cancer,NSCLC)。包括分子靶向治疗在内的传统疗法因其耐药性等问题也已进入了治疗的瓶颈时期。近年来,随着对肿瘤免疫逃逸机制的深入了解,通过阻断程序性死亡蛋白1(programmed cell death 1,PD-1)及其配体1(PD-1 ligand,PD-L1)构成的PD-1/PD-L1通路,重新激活机体免疫系统对肿瘤的杀伤作用成为了一种新的肿瘤治疗策略。目前,针对免疫检查点PD-1/PD-L1的免疫治疗在NSCLC治疗中已取得了明显的疗效,然而多项临床试验结果提示,只有约20%的NSCLC患者能从中获益。因此,探寻合适的疗效预测标志物,进而精准的选择出免疫治疗潜在的获益人群成为研究的热点。本文将对抗PD-1/PD-L1免疫治疗的疗效预测标志物在NSCLC中的研究进展做一综述。
Lung cancer is the most common malignant tumor in China and even the world,and the leading cause of cancer death worldwide.Nonsmall cell lung cancer（NSCLC） accounts for about 85%of all lung malignancies.Traditional therapies,including molecular targeted therapy,have shown more and more limitations because of the drug resistance.With the further understanding of the multiple mechanisms of tumor immune escape in recent years,blocking the programmed cell death 1（PD-1）/PD-1 ligand（PD-L1） pathway and then reactivating the tumor killing effect of immune system have been a new strategy for the treatment of cancer.Although the immunotherapy targeting the immune checkpoint PD-1/PD-L1 has achieved remarkable clinical efficacy for NSCLC,many clinical trials have showed that only about 20%of NSCLC patients can benefit from this immunotherapy.Therefore,it is a hot research topic to explore the appropriate therapeutic predictive biomarkers so as to accurately identify the potential patients suitable for this therapy.In this review,the progress in the predictive biomarkers for checkpoint blockades of PD-1 /PD-L1 pathway for patients with NSCLC is summarized.
出处
《肿瘤》
CAS
CSCD
北大核心
2016年第7期823-828,共6页
Tumor
